Amgen Ponders Whether To Seek Injunction

Law360, New York (February 8, 2007, 12:00 AM EST) -- Amgen Inc., which is embroiled in a patent infringement dispute with rival drug maker Roche Holding AG, said Thursday it is not yet sure whether to seek a preliminary injunction in the case.

Speaking at a Merrill Lynch conference, Amgen CEO Kevin Sharer acknowledged that a preliminary injunction would stop Roche from immediately launching its Mircera anemia drug. He added, however, that there were two main challenges to procuring an injunction.

“The judge could say, ‘Look, I don’t really want to hear this case twice,’” Sharer...
To view the full article, register now.